tbuckley/cabot-search huggingface dataset:
Risk of cancer associated with residential exposure to asbestos insulation: a whole-population cohort study
Authors: Rosemary J Korda, Mark S Clements, Bruce K Armstrong, Hsei Di Law, Tenniel Guiver, Philip R Anderson, Susan M Trevenar, Martyn D Kirk
Journal: The Lancet Public Health (2017)

BackgroundThe health risks associated with living in houses insulated with asbestos are unknown. Loose-fill asbestos was used to insulate some houses in the Australian Capital Territory (ACT). We compared the incidence of mesothelioma and other cancers in residents of the ACT who did and did not live in these houses.MethodsOur cohort study included all ACT residents identified using Medicare enrolment data. These data were linked to addresses of affected residential properties in the ACT to ascertain exposure. We followed up residents by linking data to the Australian Cancer Database and National Death Index. Outcomes were diagnosis of mesothelioma and selected other cancers. Effects were estimated for males and females separately using standardised incidence ratios (SIRs), adjusting for age and calendar time of diagnosis.FindingsBetween Nov 1, 1983, and Dec 31, 2013, 1 035 578 ACT residents were identified from the Medicare database. Of these, 17 248 (2%) had lived in an affected property, including seven (2%) of 285 people diagnosed with mesothelioma. The adjusted incidence of mesothelioma in males who had lived at an affected property was 2·5 times that of unexposed males (SIR 2·54, 95% CI 1·02–5·24). No mesotheliomas were reported among females who had lived at an affected property. Among individuals who had lived at an affected property, there was an elevated incidence of colorectal cancer in women (SIR 1·73, 95% CI 1·29–2·26) and prostate cancer in men (1·29, 1·07–1·54); colorectal cancer was increased, although not significantly, in males (SIR 1·32, 95% CI 0·99–1·72), with no significant increase in the other cancers studied.InterpretationResidential asbestos insulation is likely to be unsafe. Our findings have important health, social, financial, and legal implications for governments and communities in which asbestos has been used to insulate houses.FundingACT Government.
Purine Metabolism in Mouse Ascites Tumor Cells
Authors: Anna Maria Williams, G. A. LePage
Journal: Cancer Research (1958)

The in vivo incorporation of C14-labeled adenine and guanine compounds into nucleic acids and acid-soluble nucleotides was studied in Ehrlich ascites cells for incubation periods of 10–60 minutes. Corresponding to results in vitro , nucleoside was incorporated more rapidly than nucleotide, and nucleoside diluted the incorporation of nucleotide into nucleic acids more than nucleotide diluted that of nucleoside. Adenine was incorporated less rapidly than its nucleoside and nucleotide, but guanine was incorporated as well or better than guanosine and GMP. The labeling of acid-soluble nucleotides from incorporations of adenine and guanine indicated that a part of the free base was converted to mononucleotide without passing through nucleoside.

During a 10-minute period, not more than 20 per cent of totally labeled guanosine-C14 or GMP-C14 and not more than 41 per cent of AMP-C14 was incorporated into the corresponding nucleic acid nucleotide with riboside linkage intact. Some breakage occurred before and/or during incorporation of the injected precursor into acid-soluble compounds. The rate and pattern of labeling differed between base and sugar, nucleotide and nucleoside precursors, and guanine and adenine precursors. Deoxyribotides had a higher proportion of their radioactivity in the sugar moiety than did the corresponding ribotides.
TCT-200 In-Hospital Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in End Stage Renal Disease
Authors: Ahmad Alkhalil, David Song, Shervin Golbari, Harveen Lamba, Homam Ibrahim, Anas Fares, Amer Alaiti, Salil Deo, Guilherme Attizzani, Carlos Ruiz
Journal: Journal of the American College of Cardiology (2017)
Effective treatment of perianal tumors in dogs by electrochemotherapy
Authors: Gregor Sersa, Natasa Tozon, Veronika Kodre, Maja Cemazar
Journal: Cancer Research (2005)

1417   Electrochemotherapy is an antitumor therapy that utilizes chemotherapy combined with locally delivered short intense direct current electric pulse to the tumor nodule in order to enhance drug delivery into the cells. The aim of the present study was to evaluate the electrochemotherapy treatment of perianal tumors of different sizes in dogs. Between March 2000 and July 2003, 12 patients with all together 26 measurable cutaneous nodules were included in the study. Before treatment, the dogs were sedated. Electrochemotherapy consisted of intratumoral administration of cisplatin at a dose of approx. 1 mg/cm 3  tumor volume, followed by application of electric pulses to the tumor. If the treatment with cisplatin as the first chemotherapeutic drug was not successful, electrochemotherapy with bleomycin was performed; at a dose of approx. 3 mg/1 cm 3  tumor volume. Square wave electric pulses of 100 μs, 910 V amplitude, frequency 1 Hz were delivered through two parallel stainless steel electrodes (inner distance between them 7 mm) with an electroporator Jouan GHT 1287. Each run of electric pulses was delivered in two trains of 4 pulses, with 1 s interval, in two perpendicular directions. The interval between cisplatin or bleomycin administration and the application of electric pulses was 1-2 min. The treatment response was evaluated according to WHO classification (complete response (CR); partial response (PR); no change (NC) and progressive disease (PD)). The number of objective responses (OR) was determined by combining the number of CR and PR. Responses to treatment were assessed 4 weeks after the therapy, 82% of all tumors treated with electrochemotherapy responded with objective response (OR) (CR = 41%, PR = 41%), 16% responded with NC and one tumor (2%) went in PD. At the end of observation period for each tumor ranging from 1 to 34 months, 92% of OR (CR=65%, PR=27%), 8% of NC and no PD were obtained. To achieve above-mentioned results, average number of electrochemotherapy sessions was 1.6 and in range from 1 to maximum 4 sessions per patient. There were no major local or general side effects noted. This study shows that electrochemotherapy with cisplatin or bleomycin is an effective treatment of perianal tumors in dogs. The advantages of this therapy are it’s simplicity, short duration of treatment sessions, low chemotherapeutic doses, and insignificant side effects, as well as the fact that it can be performed on outpatient basis.
Association of right-sided colon cancer with poor efficacy of cetuximab in patients with <i>RAS</i> wild-type metastatic colorectal cancer.
Authors: Dalyong Kim, Yong Sang Hong, Jeong Eun Kim, Kyu-Pyo Kim, Jae-Lyun Lee, Sung-Min Chun, Jihun Kim, Se Jin Jang, Tae Won Kim
Journal: Journal of Clinical Oncology (2016)

3601 Background: Right-sided colon cancer (RC) is distinct from left-sided colorectal cancer (LC) in terms of embryology, pathology and genetics. Previous reports have shown that RC have more KRAS and BRAF mutations and poorer clinical outcomes than LC. We investigated whether primary tumor location affects cetuximab efficacy in patients with RAS wild-type (WT) metastatic colon cancer determined by extended RAS genotyping. Methods: Extended RAS analysis by SequenomMassARRAY technology platform (OncoMap) targeting KRAS (exon 2, 3, 4), NRAS (exon 2, 3, 4), PIK3CA and BRAF (exon 15) was performed in tumors from 307 patients treated with cetuximab as salvage treatment. Tumors with mutated RAS (n = 127) and synchronous primary tumors (n = 10) were excluded. The border of right-sided colon and left-sided colon was defined as splenic flexure. Results: A total of 170 patients were included (RC versus LC, 23 and 147). More mutant BRAF (39.1% vs. 5.4%), poorly differentiated (17.4% vs. 3.4%) and mutant PIK3CA (13% vs. 1.4%) tumor and peritoneal involvement (26.1% vs. 8.8%) were observed in RC. Progression-free survival (PFS) was significantly shorter in RC (2.0 vs 4.9 months, P = 0.004). Overall survival (OS) was 4.1 months in RC and 13.0 months in LC (P = 0.002). In multivariate analysis, BRAF mutations, RC, poorly differentiated histology and peritoneal involvement were associated with shorter overall survival (adjusted hazard ratios, 2.96, 1.63, 2.97 and 2.12, respectively). Conclusions: In RAS WT colon cancer treated with cetuximab as salvage treatment, right-sided colon cancer had a poor survival. Further investigation is required to verify the difference in cetuximab efficacy according to primary site of metastatic colorectal cancer.
Influence of ejection fraction on cause‐specific mortality in heart failure with preserved ejection fraction
Authors: Navkaranbir S. Bajaj, Brian Claggett, Eldrin F. Lewis, Akshay S. Desai, James C. Fang, Eileen O'Meara, Sanjiv J. Shah, Nancy K. Sweitzer, Jerome L. Fleg, Bertram Pitt, Jean L. Rouleau, Peter Finn, Marc A. Pfeffer, Scott D. Solomon
Journal: European Journal of Heart Failure (2017)
Making replication mainstream
Authors: Rolf A. Zwaan, Alexander Etz, Richard E. Lucas, M. Brent Donnellan
Journal: Behavioral and Brain Sciences (2017)

We discuss the authors' conceptualization of replication, in particular the false dichotomy of direct versus conceptual replication intrinsic to it, and suggest a broader one that better generalizes to other domains of psychological research. We also discuss their approach to the evaluation of replication results and suggest moving beyond their dichotomous statistical paradigms and employing hierarchical / meta-analytic statistical models.
Breast Implant–Associated Anaplastic Large Cell Lymphoma
Authors: Ashley N. Leberfinger, Brittany J. Behar, Nicole C. Williams, Kevin L. Rakszawski, John D. Potochny, Donald R. Mackay, Dino J. Ravnic
Journal: JAMA Surgery (2017)

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare peripheral T-cell lymphoma, is increasing in incidence. However, many practitioners who treat patients with breast cancer are not aware of this disease.To assess how BIA-ALCL develops, its risk factors, diagnosis, and subsequent treatment and to disseminate information about this entity to the medical field.A literature review was performed in an academic medical setting. All review articles, case reports, original research articles, and any other articles relevant to BIA-ALCL were included. Data on BIA-ALCL, such as pathophysiology, patient demographics, presentation, diagnosis, treatment, and outcomes, were extracted. Particular focus was paid to age, time to onset, implant type, initial symptoms, treatment, and survival. The search was conducted in January 2017 for studies published in any year.After duplicates were excluded, 304 relevant articles were assessed, and 115 were included from the first documented case in August 1997 through January 2017. Thirty review articles, 44 case reports or series, 15 original research articles, and 26 "other" articles (eg, techniques, special topics, letters) were reviewed. A total of 93 cases have been reported in the literature, and with the addition of 2 unreported cases from the Penn State Health Milton S. Hershey Medical Center, 95 patients were included in this systematic review. Almost all documented BIA-ALCL cases have been associated with a textured device. The underlying mechanism is thought to be due to chronic inflammation from indolent infections, leading to malignant transformation of T cells that are anaplastic lymphoma kinase (ALK) negative and CD30 positive. The mean time to presentation is approximately 10 years after implant placement, with 55 of 83 (66%) patients initially seen with an isolated late-onset seroma and 7 of 83 (8%) with an isolated new breast mass. Ultrasonography with fluid aspiration can be used for diagnosis. Treatment must include removal of the implant and surrounding capsule. More advanced disease may require chemotherapy, radiotherapy, and lymph node dissection.Breast implant-associated anaplastic large cell lymphoma is a rare cancer in patients with breast implants but is increasing in incidence. It is important for all physicians involved in the care of patients with breast implants to be aware of this entity and be able to recognize initial symptoms.
HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells
Authors: Rebecca T. Veenhuis, Zachary T. Freeman, Jack Korleski, Laura K. Cohen, Guido Massaccesi, Alessandra Tomasi, Austin W. Boesch, Margaret E. Ackerman, Joseph B. Margolick, Joel N. Blankson, Michael A. Chattergoon, Andrea L. Cox
Journal: Journal of Clinical Investigation (2017)

Type I IFN production is essential for innate control of acute viral infection; however, prolonged high-level IFN production is associated with chronic immune activation in HIV-infected individuals. Although plasmacytoid DCs (pDCs) are a primary source of IFN, the mechanisms that regulate IFN levels following the acute phase are unknown. We hypothesized that HIV-specific Ab responses regulate late IFN production. We evaluated the mechanism through which HIV-activated pDCs produce IFN as well as how both monoclonal HIV-specific Abs and Abs produced in natural HIV infection modulated normal pDC sensing of HIV. We found that HIV-induced IFN production required TLR7 signaling, receptor-mediated entry, fusion, and viral uncoating, but not endocytosis or HIV life cycle stages after uncoating. Abs directed against the HIV envelope that do not interfere with CD4 binding markedly enhanced the IFN response, irrespective of their ability to neutralize CD4+ T cell infection. Ab-mediated enhancement of IFN production required Fc γ receptor engagement, bypassed fusion, and initiated signaling through both TLR7 and TLR9, which was not utilized in the absence of Ab. Polyclonal Abs isolated from HIV-infected subjects also enhanced pDC production of IFN in response to HIV. Our data provide an explanation for high levels of IFN production and immune activation in chronic HIV infection.
TCT-301 Long-term outcomes of chronic total occlusion percutaneous coronary intervention in patients with vs. without prior coronary artery bypass graft surgery
Authors: Lorenzo Azzalini, Soledad Ojeda, Aris Karatasakis, Joren Maeremans, Masaki Tanabe, Alessio La Manna, Luiz Ybarra, Rustem Dautov, Susanna Benincasa, Barbara Bellini, Luciano Candilio, Francisco Hidalgo, Giacomo Gravina, Eligio Miccichè, Guido D'Agosta, Corrado Tamburino, Manuel Pan, Joseph Dens, Mauro Carlino, Emmanouil Brilakis, Antonio Colombo, Stéphane Rinfret
Journal: Journal of the American College of Cardiology (2017)
Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer—Reply
Authors: Michael P. Chu, Michael B. Sawyer
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Effect of morphine on breathlessness and exercise endurance in advanced COPD: a randomised crossover trial
Authors: Sara J. Abdallah, Courtney Wilkinson-Maitland, Nathalie Saad, Pei Zhi Li, Benjamin M. Smith, Jean Bourbeau, Dennis Jensen
Journal: European Respiratory Journal (2017)

The objective of the present study was to evaluate the effect of morphine on exertional breathlessness and exercise endurance in advanced chronic obstructive pulmonary disease (COPD). In a randomised crossover trial, we compared the acute effect of immediate-release oral morphine versus placebo on physiological and perceptual responses during constant-load cardiopulmonary cycle exercise testing (CPET) in 20 adults with advanced COPD and chronic breathlessness syndrome. Compared with placebo, morphine reduced exertional breathlessness at isotime by 1.2±0.4 Borg units and increased exercise endurance time by 2.5±0.9 min (both p≤0.014). During exercise at isotime, morphine decreased ventilation by 1.3±0.5 L·min −1 and breathing frequency by 2.0±0.9 breaths·min −1 (both p≤0.041). Compared with placebo, morphine decreased exertional breathlessness at isotime by ≥1 Borg unit in 11 participants (responders) and by &lt;1 Borg unit in nine participants (non-responders). Baseline participant characteristics, including pulmonary function and cardiorespiratory fitness, were similar between responders and non-responders. A higher percentage of responders versus non-responders stopped incremental CPET due to intolerable breathlessness: 82 versus 33% (p=0.028). Immediate-release oral morphine improved exertional breathlessness and exercise endurance in some, but not all, adults with advanced COPD. The locus of symptom-limitation on laboratory-based CPET may help to identify patients most likely to benefit from morphine.
Improving Direct-to-Consumer Medical Testing
Authors: Ann M. Gronowski, Shannon Haymond, Stephen R. Master
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Characterization of Cardiac Dynamics in an Acute Myocardial Infarction Model by Four-Dimensional Optoacoustic and Magnetic Resonance Imaging
Authors: Hsiao-Chun Amy Lin, Xosé Luís Déan-Ben, Ivana Ivankovic, Melanie A. Kimm, Katja Kosanke, Helena Haas, Reinhard Meier, Fabian Lohöfer, Moritz Wildgruber, Daniel Razansky
Journal: Theranostics (2017)

Extraction of murine cardiac functional parameters on a beat-by-beat basis is limited with the existing imaging modalities due to insufficient three-dimensional temporal resolution.Faster volumetric imaging methods enabling in vivo characterization of functional parameters are poised to advance cardiovascular research and provide a better understanding of the mechanisms underlying cardiac diseases.We present a new approach based on analyzing contrast-enhanced optoacoustic (OA) images acquired at high volumetric frame rate without using cardiac gating or other approaches for motion correction.We apply an acute murine myocardial infarction model optimized for acquisition of artifact-free optoacoustic imaging data to study cardiovascular hemodynamics.Infarcted hearts (n = 21) could be clearly differentiated from healthy controls (n = 9) based on a significantly higher pulmonary transit time (PTT) (2.25 [2.00-2.41]s versus 1.34 [1.25-1.67]s, p = 0.0235), while no statistically significant difference was observed in the heart rate (318 [252-361] bpm versus 264 [252-320] bpm, p = 0.3129).Nevertheless, nonlinear heartbeat dynamics was stronger in the healthy hearts, as evidenced by the third harmonic component in the heartbeat spectra.MRI data acquired from the same mice further revealed that the PTT increases with the size of infarction and similarly increases with reduced ejection fraction.Moreover, an inverse relationship between infarct PTT and time post-surgery was found, which suggests the occurrence of cardiac healing.In combination with the proven ability of optoacoustics to track targeted probes within the injured myocardium, our method can depict cardiac anatomy, function, and molecular signatures, with both high spatial and temporal resolution.Volumetric four-dimensional optoacoustic characterization of cardiac dynamics with supreme temporal resolution can capture cardiovascular dynamics on a beat-by-beat basis in mouse models of myocardial ischemia.
Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM
Authors: Kyung-A Song, Matthew J. Niederst, Timothy L. Lochmann, Aaron N. Hata, Hidenori Kitai, Jungoh Ham, Konstantinos V. Floros, Mark A. Hicks, Haichuan Hu, Hillary E. Mulvey, Yotam Drier, Daniel A.R. Heisey, Mark T. Hughes, Neha U. Patel, Elizabeth L. Lockerman, Angel Garcia, Shawn Gillepsie, Hannah L. Archibald, Maria Gomez-Caraballo, Tara J. Nulton, Brad E. Windle, Zofia Piotrowska, Sinem E. Sahingur, Shirley M. Taylor, Mikhail Dozmorov, Lecia V. Sequist, Bradley Bernstein, Hiromichi Ebi, Jeffrey A. Engelman, Anthony C. Faber
Journal: Clinical Cancer Research (2017)

Epithelial-to-mesenchymal transition (EMT) confers resistance to a number of targeted therapies and chemotherapies. However, it has been unclear why EMT promotes resistance, thereby impairing progress to overcome it.
Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes: A cross sectional and a prospective case-control study nested in the Normative Aging Study
Authors: Ayse Sahin-Efe, Jagriti Upadhyay, Byung-Joon Ko, Fadime Dincer, Kyung Hee Park, Alexandra Migdal, Pantel Vokonas, Christos Mantzoros
Journal: Metabolism (2017)
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
Authors: Yung-Jue Bang, Rui-Hua Xu, Keisho Chin, Keun-Wook Lee, Se Hoon Park, Sun Young Rha, Lin Shen, Shukui Qin, Nong Xu, Seock-Ah Im, Gershon Locker, Phil Rowe, Xiaojin Shi, Darren Hodgson, Yu-Zhen Liu, Narikazu Boku
Journal: The Lancet Oncology (2017)
Sorveglianza della sindrome emolitico-uremica in bambini sotto i 15 anni d'età in Francia, 1998
Authors: S Haeghebaert, V Vaillant, B Decludt, P. A.D. Grimont
Journal: Eurosurveillance (2000)

In Francia, i dati di una rete nazionale di reparti di nefrologia pediatrica suggeriscono che, nel 1998, l'incidenza della sindrome emolitico-uremica (SEU) sia stata di 0,7 casi ogni 100.000 bambini con eta inferiore ai 15 anni e che i casi si siano verificati in maniera sporadica. Tra gli 85 casi notificati nel 1998, sei erano importati; cio spiega la necessita di sistemi nazionali e internazionali di allerta per la SEU. Dal 1996, quando e stato istituito questo sistema di sorveglianza, e diminuita la proporzione di casi sieropositivi. Questo suggerisce che nuovi sierogruppi di Escherichia coli, non identificabili dai sistemi diagnostici sierologici attualmente utilizzati, possano essere responsabili di alcuni casi di SEU.